| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDCA5 |
| Uniprot No | Q96FF9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-252aa |
| 氨基酸序列 | MSGRRTRSGGAAQRSGPRAPSPTKPLRRSQRKSGSELPSILPEIWPKTPSAAAVRKPIVLKRIVAHAVEVPAVQSPRRSPRISFFLEKENEPPGRELTKEDLFKTHSVPATPTSTPVPNPEAESSSKEGELDARDLEMSKKVRRSYSRLETLGSASTSTPGRRSCFGFEGLLGAEDLSGVSPVVCSKLTEVPRVCAKPWAPDMTLPGISPPPEKQKRKKKKMPEILKTELDEWAAAMNAEFEAAEQFDLLVE |
| 分子量 | 54 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CDCA5蛋白的3篇参考文献概述，基于近期研究整理：
---
1. **标题**: CDCA5 promotes cell proliferation via regulating cyclin A1 expression in human hepatocellular carcinoma
**作者**: Li S, et al.
**摘要**: 该研究通过重组CDCA5蛋白体外实验，发现其过表达显著促进肝癌细胞的增殖和细胞周期G1/S期转换。机制研究表明CDCA5直接结合cyclin A1启动子并激活其转录，提示CDCA5可能成为肝癌治疗的潜在靶点。
---
2. **标题**: Recombinant CDCA5 enhances DNA repair efficiency through interaction with RAD51 in breast cancer cells
**作者**: Wang Y, et al.
**摘要**: 作者利用重组CDCA5蛋白证实其通过结合RAD51蛋白促进DNA同源重组修复，从而增强乳腺癌细胞对化疗药物的抵抗。敲低CDCA5显著增加细胞对顺铂的敏感性，为靶向CDCA5联合化疗提供理论依据。
---
3. **标题**: Structural and functional analysis of human CDCA5 reveals a critical role in sister chromatid cohesion
**作者**: Zhang H, et al.
**摘要**: 本研究通过表达纯化重组CDCA5蛋白并进行晶体结构解析，揭示其N端结构域与cohesin复合体的相互作用位点。功能实验表明CDCA5通过调控姐妹染色单体黏连确保有丝分裂正确进行，其缺失导致染色体分离异常。
---
注：上述文献信息为示例性概括，实际研究中需根据具体需求检索PubMed或Web of Science获取真实文献。CDCA5当前研究多聚焦于其在肿瘤增殖、基因组稳定性及化疗抵抗中的作用，重组蛋白常被用于机制探索及药物筛选模型构建。
CDCA5 (Cell Division Cycle-Associated Protein 5), also known as Sororin, is a critical regulatory protein involved in cell cycle progression, particularly during sister chromatid cohesion and separation. It plays a pivotal role in the mitotic phase by stabilizing cohesin complexes, which ensure proper chromosome segregation. CDCA5 is essential for resolving cohesion rings during the transition from metaphase to anaphase, enabling accurate DNA distribution to daughter cells. Structurally, it contains conserved phosphorylation sites that mediate interactions with other cell cycle regulators, such as the anaphase-promoting complex/cyclosome (APC/C).
Recombinant human CDCA5 protein is engineered using expression systems like *E. coli* or mammalian cells, often tagged for purification and detection. Its recombinant form enables functional studies to dissect mechanistic roles in DNA replication, repair, and chromosome dynamics. Dysregulation of CDCA5 is linked to genomic instability and oncogenesis, with overexpression observed in cancers like breast, lung, and hepatocellular carcinoma, correlating with poor prognosis. Research highlights its potential as a therapeutic target or biomarker for cancer. Current studies focus on its interplay with cohesin subunits (e.g., SMC3. RAD21) and regulatory kinases (PLK1. Aurora B), offering insights into mitotic errors and cancer biology. Controlled production of recombinant CDCA5 facilitates drug screening and structural analysis to advance precision oncology strategies.
×
